Comparing the current results to its competitors, Rocket Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 17.79 %, recorded in the same quarter.
May 10, 2025
In an era where genetic therapy promises revolutionary breakthroughs in treating rare diseases, Rocket Pharmaceuticals, Inc. has found itself at a pivotal junction. The firm, known for developing therapies for genetic disorders, spotlighted its promising advancements by announcing an upcoming oral presentation of its Phase 1 clinical trial data for RP-A601, which aims to address plakophilin2-related arrhythmogenic cardiomyopathy (PKP2ACM). This presentation, set for the 28th Annual Meeting of the American Society of Gene and Cell Therapy, heralds a significant moment for both the company and the broader field of genetic medicine. Emerging Therapeutics Amid Industry Competition Rocket s foray into PKP2ACM the...
December 11, 2024
Rocket Pharmaceuticals Expands Horizons: Strategic Offerings and Pivotal Trials Propel Company Forward in Genetic Therapy for Rare Disorders In a significant stride towards advancing its innovative pipeline, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated and late-stage biotechnology company, has made waves in recent weeks with a series of strategic initiatives aimed at addressing rare disorders that pose substantial challenges for patients and their families. The company’s commitment to discovering and developing transformative genetic therapies is underscored by its recent upsized public offering, the completion of patient enrollment in a pivotal clinical trial, and its reported financial...
August 5, 2024
Advancing Genetic Therapies for Rare Disorders: An In-Depth Look at Rocket Pharmaceuticals’ Second Quarter 2024 Progress and Financial Performance Rocket Pharmaceuticals, Inc., a notable entity in the late-stage biotechnology sector focused on genetic therapies, has recently unveiled its financial results and operational achievements for the second quarter of 2024. This article aims to explore the implications of these results, particularly concerning the ongoing development of Rocket’s innovative pipeline targeting rare diseases, including Danon disease and PKP2-associated Arrhythmogenic Cardiomyopathy (PKP2-ACM). The field of biotechnology has become increasingly pivotal in addressing rare genetic d...
February 13, 2024
Rocket Pharmaceuticals Faces Delays in FDA Review of Promising Rare Disease TreatmentRocket Pharmaceuticals, a leading biotechnology company focused on genetic therapies for rare disorders, recently announced that the U.S. Food and Drug Administration (FDA) has extended its Priority Review period for their Biologics License Application (BLA) for KRESLADI (marnetegragene autotemcel). This setback has potential implications for the treatment of severe Leukocyte Adhesion Deficiency-I (LAD-I), a rare and life-threatening condition.LAD-I is a genetic disorder characterized by a malfunctioning immune system, specifically the adhesive capabilities of white blood cells. This deficiency makes individuals highly susce...
Publicly Traded Peers of Rocket Pharmaceuticals Inc
United Therapeutics Corporation Share Performance
-9.96%
This Quarter
United Therapeutics Corporation
Profile
United Therapeutics Corporation's business model revolves around the development and commercialization of innovative therapeutics for treating rare diseases and chronic conditions. They focus on researching, manufacturing, marketing, and distributing their specialized pharmaceutical and medical products to healthcare providers and patients globally.
Cytokinetics Incorporated is a biopharmaceutical company with a business model centered around the discovery and development of novel muscle activators. They strive to improve the lives of patients with debilitating diseases by focusing on the development of potentially life-changing therapies. Cytokinetics aims to achieve commercial success by leveraging its expertise in muscle biology and utilizing strategic collaborations to bring their innovative therapies to market.
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using its CRISPR/Cas9 gene-editing platform. They aim to leverage the potential of CRISPR to treat severe genetic diseases by directly modifying genes within the body's cells. The company collaborates with partners, conducts research and development of their therapeutics, and ultimately aims to bring their innovative treatments to market.
Corcept Therapeutics Inc operates using a business model that focuses primarily on the research, development, and commercialization of pharmaceutical products. The company aims to discover and develop medications for conditions related to cortisol dysregulation, with a specific focus on Cushing's syndrome and psychiatric disorders. Additionally, Corcept Therapeutics Inc aims to ensure the successful commercialization of their products through collaborations and partnerships with other organizations to reach a wider market.
Sources:
Rocket Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Rocket Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
